Published in:
Open Access
01-12-2020 | Levofloxacin | Case report
Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report
Authors:
Kana Kurokawa, Norihiro Harada, Hitoshi Sasano, Haruhi Takagi, Satomi Takei, Ayako Nakamura, Keisuke Kamada, Atsushi Yoshida, Ken Kikuchi, Kazuhisa Takahashi
Published in:
BMC Infectious Diseases
|
Issue 1/2020
Login to get access
Abstract
Background
Mycolicibacterium fortuitum is a species of the rapidly growing mycobacteria that can cause pulmonary infection. It is susceptible to multiple antibiotics both in vitro and in clinical practice, so that any combination of susceptible drugs is effective. However, we encountered a case of infection due to fluoroquinolone-resistant M. fortuitum. In this study, we report the case and describe the mechanism of resistance.
Case presentation
A 65-year-old man with a history of total gastrectomy and immunosuppressant treatment for rheumatoid arthritis developed a recurrence of pulmonary infection caused by M. fortuitum. He was treated with clarithromycin and levofloxacin as a first-line treatment, based on the favorable susceptibility at that time. After recurrence, a high minimum inhibitory concentration to fluoroquinolones was detected. DNA sequencing of the pathogen showed the substitution of serine for tryptophan at residue 83 in the gyrA gene. He was successfully treated with a combination of other antibiotics.
Conclusion
This is the first report on the treatment of fluoroquinolone-resistant M. fortuitum and investigation of the mechanism of resistance. We suggest that the susceptibility test remains effective for determining the next line of treatment after a pathogen has acquired resistance, and resistance to fluoroquinolones in M. fortuitum can be attributed to a single change of amino acid.